Published in Neoplasia on May 01, 2007
A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol (2009) 2.10
New insights into tumor microstructure using temporal diffusion spectroscopy. Cancer Res (2008) 1.25
Earlier detection of tumor treatment response using magnetic resonance diffusion imaging with oscillating gradients. Magn Reson Imaging (2010) 0.99
On the relationship between the apparent diffusion coefficient and extravascular extracellular volume fraction in human breast cancer. Magn Reson Imaging (2011) 0.92
Dynamic contrast-enhanced and diffusion-weighted MRI for early detection of tumoral changes in single-dose and fractionated radiotherapy: evaluation in a rat rhabdomyosarcoma model. Eur Radiol (2009) 0.91
Diffusion MRI and novel texture analysis in osteosarcoma xenotransplants predicts response to anti-checkpoint therapy. PLoS One (2013) 0.86
Assessment of multiexponential diffusion features as MRI cancer therapy response metrics. Magn Reson Med (2010) 0.85
Effect of b value on monitoring therapeutic response by diffusion-weighted imaging. World J Gastroenterol (2008) 0.83
Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study. Radiat Oncol (2011) 0.82
High-field small animal magnetic resonance oncology studies. Phys Med Biol (2013) 0.81
Combined value of apparent diffusion coefficient-standardized uptake value max in evaluation of post-treated locally advanced rectal cancer. World J Radiol (2015) 0.80
Multimodal functional imaging for early response assessment in GIST patients treated with imatinib. Acta Oncol (2013) 0.79
Early changes in apparent diffusion coefficient as an indicator of response to sorafenib in hepatocellular carcinoma. J Zhejiang Univ Sci B (2014) 0.76
Neoplasia: the second decade. Neoplasia (2008) 0.75
The War on Cancer rages on. Neoplasia (2009) 0.75
Early changes in the apparent diffusion coefficient and MMP-9 expression of a cervical carcinoma U14 allograft model following irradiation. Oncol Lett (2017) 0.75
Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med (2004) 25.68
Estimating the world cancer burden: Globocan 2000. Int J Cancer (2001) 16.92
Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med (2001) 13.75
The mesorectum in rectal cancer surgery--the clue to pelvic recurrence? Br J Surg (1982) 8.69
Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology (1988) 8.08
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer (1998) 5.40
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst (2000) 5.14
Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med (2000) 3.34
Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer (2004) 3.06
Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet (2002) 2.38
The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia (2006) 2.30
Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther (2003) 2.28
Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia (1999) 2.24
Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. Br J Cancer (1996) 2.20
Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia (2005) 2.17
A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol (2005) 2.09
Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging (1999) 2.07
Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol (2005) 1.95
X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res (1999) 1.81
Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia (2000) 1.72
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist (2002) 1.70
Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol (2003) 1.67
Monitoring thymidine kinase and ganciclovir-induced changes in rat malignant glioma in vivo by nuclear magnetic resonance imaging. Cancer Gene Ther (1998) 1.62
Apparent diffusion coefficient: a quantitative parameter for in vivo tumor characterization. Eur J Radiol (2003) 1.50
Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia (2005) 1.45
Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol (2003) 1.40
Monitoring cytotoxic tumour treatment response by diffusion magnetic resonance imaging and proton spectroscopy. NMR Biomed (2002) 1.34
Diffusion imaging for evaluation of tumor therapies in preclinical animal models. MAGMA (2004) 1.33
Applications of magnetic resonance in model systems: tumor biology and physiology. Neoplasia (2000) 1.25
In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemother Pharmacol (2005) 1.24
A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol (2003) 1.20
Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration. Neoplasia (2005) 1.18
The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been? Ann Oncol (2006) 1.15
Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys (2002) 1.08
In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line. Acta Oncol (2005) 0.99
Locally advanced rectal carcinoma: pelvic control and morbidity following preoperative radiation therapy, resection, and intraoperative radiation therapy. Int J Radiat Oncol Biol Phys (1997) 0.98
Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation. Ann Oncol (2006) 0.96
In vivo measurement of diffusion and pseudo-diffusion in skeletal muscle at rest and after exercise. Magn Reson Imaging (1995) 0.96
Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol (2003) 0.95
A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol (2005) 0.92
Oxaliplatin-5-fluorouracil and ionizing radiation. Importance of the sequence and influence of p53 status. Oncology (2003) 0.88
A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma. Int J Radiat Oncol Biol Phys (2006) 0.82
Oxaliplatin-based combined-modality therapy for rectal cancer. Semin Oncol (2003) 0.79
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol (2010) 2.09
A method for measurement of the uptake patterns of two beta-emitting radionuclides in the same tissue section with a digital silicon detector: application to a study of 89SrCl2 and 153Sm-EDTMP in a dog with spontaneous osteosarcoma. Eur J Nucl Med Mol Imaging (2002) 1.51
Optimal use of AEC in CT: a literature review. Radiol Technol (2010) 1.44
Radiation therapy induced changes in male sex hormone levels in rectal cancer patients. Radiother Oncol (2003) 1.40
Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res (2005) 1.32
Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer (2012) 1.30
MicroRNAs as biomarkers in colorectal cancer. Am J Pathol (2010) 1.25
Iterative reconstruction reduces abdominal CT dose. Eur J Radiol (2011) 1.24
Deep Sequencing the MicroRNA Transcriptome in Colorectal Cancer. PLoS One (2013) 1.22
Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Acta Oncol (2010) 1.21
The updated ESTRO core curricula 2011 for clinicians, medical physicists and RTTs in radiotherapy/radiation oncology. Radiother Oncol (2012) 1.16
Adapting radiotherapy to hypoxic tumours. Phys Med Biol (2006) 1.14
Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition. Radiat Oncol (2006) 1.13
Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling. Int J Radiat Oncol Biol Phys (2010) 1.13
Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study. Phys Med Biol (2006) 1.08
Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer. Clin Colorectal Cancer (2013) 1.08
Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status. Int J Radiat Oncol Biol Phys (2009) 1.05
Preoperative irradiation and surgery for recurrent rectal cancer. Will intraoperative radiotherapy (IORT) be of additional benefit? A prospective study. Radiother Oncol (2002) 1.03
B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer. Int J Cancer (2012) 1.01
Radiotherapy adapted to spatial and temporal variability in tumor hypoxia. Int J Radiat Oncol Biol Phys (2007) 0.99
Nuclear S100A4 is a novel prognostic marker in colorectal cancer. Eur J Cancer (2010) 0.99
Dose painting: art or science? Radiother Oncol (2006) 0.97
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. J Enzyme Inhib Med Chem (2014) 0.96
Respiratory motion prediction by using the adaptive neuro fuzzy inference system (ANFIS). Phys Med Biol (2005) 0.95
Nuclear legumain activity in colorectal cancer. PLoS One (2013) 0.95
Breath actuated device improves delivery to target sites beyond the nasal valve. Laryngoscope (2006) 0.92
Integrin scintimammography using a dedicated breast imaging, solid-state gamma-camera and (99m)Tc-labelled NC100692. Clin Physiol Funct Imaging (2008) 0.91
Reconstruction of a ring applicator using CT imaging: impact of the reconstruction method and applicator orientation. Phys Med Biol (2007) 0.89
Strategies for biologic image-guided dose escalation: a review. Int J Radiat Oncol Biol Phys (2009) 0.89
Open versus laparoscopic liver resection for colorectal liver metastases (the Oslo-CoMet Study): study protocol for a randomized controlled trial. Trials (2015) 0.89
Molecular modelling and simulations in cancer research. Biochim Biophys Acta (2013) 0.88
Bi-directional nasal delivery of aerosols can prevent lung deposition. J Aerosol Med (2004) 0.88
Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy. Radiat Oncol (2011) 0.88
Brachytherapy for prostate cancer: a systematic review of clinical and cost effectiveness. Eur Urol (2003) 0.88
Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma. PLoS One (2013) 0.88
Quantification of angiogenesis in breast cancer by automated vessel identification in CD34 immunohistochemical sections. Anticancer Res (2011) 0.87
Automatic segmentation and recognition of lungs and lesion from CT scans of thorax. Comput Med Imaging Graph (2008) 0.87
Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump. J Aerosol Med Pulm Drug Deliv (2012) 0.87
Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients. Lung Cancer (2008) 0.87
A simulation of MRI based dose calculations on the basis of radiotherapy planning CT images. Acta Oncol (2008) 0.87
Liposomal doxorubicin improves radiotherapy response in hypoxic prostate cancer xenografts. Radiat Oncol (2011) 0.87
Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity? Radiother Oncol (2007) 0.86
Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites. Tumour Biol (2009) 0.86
The clinical impact of mean vessel size and solidity in breast carcinoma patients. PLoS One (2013) 0.86
B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome. BMC Cancer (2014) 0.86
Correction of partial volume effect in (18)F-FDG PET brain studies using coregistered MR volumes: voxel based analysis of tracer uptake in the white matter. Neuroimage (2013) 0.85
Monitoring the effect of targeted therapies in a gastrointestinal stromal tumor xenograft using a clinical PET/CT. Mol Imaging Biol (2011) 0.85
Low dose hyper-radiosensitivity is eliminated during exposure to cycling hypoxia but returns after reoxygenation. Int J Radiat Biol (2012) 0.85
Establishment and characterization of a human gastrointestinal stromal tumour (GIST) xenograft in athymic nude mice. Anticancer Res (2009) 0.85
Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination. Angiogenesis (2011) 0.85
Mechanisms of the elimination of low dose hyper-radiosensitivity in T-47D cells by low dose-rate priming. Int J Radiat Biol (2009) 0.84
HDAC2 deficiency and histone acetylation. Nat Genet (2008) 0.84
Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer. Int J Radiat Oncol Biol Phys (2013) 0.84
Late effects after radiotherapy for locally advanced cervical cancer: comparison of two brachytherapy schedules and effect of dose delivered weekly. Int J Radiat Oncol Biol Phys (2009) 0.83
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma. Radiat Oncol (2012) 0.83
Adapting biological feedback in radiotherapy. Semin Radiat Oncol (2010) 0.83
Teleradiology with satellite units - six years experience at the norwegian radium hospital. Stud Health Technol Inform (2008) 0.82
The elimination of low-dose hyper-radiosensitivity by transfer of irradiated-cell conditioned medium depends on dose rate. Radiat Res (2009) 0.82
Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy. Nucl Med Biol (2006) 0.81
The metastasis-associated protein S100A4 exists in several charged variants suggesting the presence of posttranslational modifications. BMC Cancer (2008) 0.81
Noninvasive monitoring of radiation-induced treatment response using proton magnetic resonance spectroscopy and diffusion-weighted magnetic resonance imaging in a colorectal tumor model. Radiother Oncol (2007) 0.80
Detection of disseminated tumour cells in bone marrow of patients with isolated liver metastases from colorectal cancer. J Surg Oncol (2003) 0.79
Associations between tumor vascularization assessed by in vivo DCE-MRI and the presence of disseminated tumor cells in bone marrow in breast cancer patients at the time of diagnosis. J Magn Reson Imaging (2014) 0.79
Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer. PLoS One (2013) 0.79
Dose optimisation in single plane interstitial brachytherapy. Radiother Oncol (2006) 0.78
Modifications in dynamic contrast-enhanced magnetic resonance imaging parameters after α-particle-emitting ²²⁷Th-trastuzumab therapy of HER2-expressing ovarian cancer xenografts. Int J Radiat Oncol Biol Phys (2013) 0.78
The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells. J Ovarian Res (2014) 0.78
Dynamic respiratory gated (18)FDG-PET of lung tumors - a feasibility study. Acta Oncol (2011) 0.78
Impact of hyperthermia on pharmacokinetics of intraperitoneal mitomycin C in rats investigated by microdialysis. J Surg Oncol (2013) 0.78
Leveraging clinical performance by technological excellence - The case of particle therapy. Radiother Oncol (2010) 0.77
DNA damage responses in cell cycle G2 phase and mitosis--tracking and targeting. Anticancer Res (2006) 0.77
Ultrasound enhanced antitumor activity of liposomal doxorubicin in mice. J Drug Target (2011) 0.77
Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma. Virchows Arch (2012) 0.77
Studies on the synthesis and biological properties of non-carrier-added [(125)I and (131)I]-labeled arylalkylidenebisphosphonates: potent bone-seekers for diagnosis and therapy of malignant osseous lesions. J Med Chem (2003) 0.77
Artificial neural networks for prediction of response to chemoradiation in HT29 xenografts. Int J Radiat Oncol Biol Phys (2009) 0.77
Biology-guided adaptive radiation therapy - presence or future? Acta Oncol (2010) 0.77
Cell cycle inhibitors and outcome after radiotherapy in bladder cancer patients. Acta Oncol (2002) 0.77
'Intensity diffusion' is a better description than 'partial volume effect'. Eur J Nucl Med Mol Imaging (2009) 0.76
MR-guided simultaneous integrated boost in preoperative radiotherapy of locally advanced rectal cancer following neoadjuvant chemotherapy. Radiother Oncol (2009) 0.76
Routine pelvic MRI using phased-array coil for detection of extraprostatic tumour extension: accuracy and clinical significance. Eur Radiol (2012) 0.76
Radiosensitizing drugs: lessons to be learned from the oxaliplatin story. J Clin Oncol (2010) 0.76
DCEMRI of spontaneous canine tumors during fractionated radiotherapy: a pharmacokinetic analysis. Radiother Oncol (2009) 0.76
Characterization of an asymmetric add-on collimator used with a hand-held gamma probe for radioguided surgery and sentinel node detection: a demonstration of an alternative collimation method. Clin Physiol Funct Imaging (2013) 0.76
Late regional density changes of the lung after radiotherapy for breast cancer. Radiother Oncol (2008) 0.75
Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer. PLoS One (2012) 0.75